Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Expert Perspectives on Integrating Immuno-Oncology Therapeutics Into the Management of Metastatic Triple-Negative Breast Cancer

Sarah Donahue, MPH, NP
David B. Page, MD
Hope S. Rugo, MD
Peter Schmid, MD, PhD, FRCP
Released: May 14, 2020
Back Next

Introduction

In these highlights from the ClinicalThought program, Sarah Donahue, MPH, NP; David B. Page, MD; Hope S. Rugo, MD; and Peter Schmid, MD, PhD, FRCP, discuss the latest developments in immuno-oncology strategies for managing metastatic triple-negative breast cancer (TNBC), including optimal use of immune checkpoint inhibition, toxicity management, and future directions.

CCO plans to measure the educational impact of this activity, and some questions in this activity will be asked twice: once prior to the discussion that informs the best choice and then once again after that specific discussion. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

Back Next
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@clinicaloptions.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Genentech

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue